239 related articles for article (PubMed ID: 19824039)
21. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
[TBL] [Abstract][Full Text] [Related]
22. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
23. SseL is a salmonella-specific translocated effector integrated into the SsrB-controlled salmonella pathogenicity island 2 type III secretion system.
Coombes BK; Lowden MJ; Bishop JL; Wickham ME; Brown NF; Duong N; Osborne S; Gal-Mor O; Finlay BB
Infect Immun; 2007 Feb; 75(2):574-80. PubMed ID: 17158898
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
25. Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma.
Zhu X; Zhou P; Cai J; Yang G; Liang S; Ren D
Cancer Sci; 2010 Dec; 101(12):2621-8. PubMed ID: 20880334
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
27. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein.
Chou CK; Hung JY; Liu JC; Chen CT; Hung MC
Cancer Gene Ther; 2006 Aug; 13(8):746-52. PubMed ID: 16410824
[TBL] [Abstract][Full Text] [Related]
28. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
29. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
30. The use of live attenuated Salmonella for oral vaccination.
Chatfield S; Roberts M; Li J; Starns A; Dougan G
Dev Biol Stand; 1994; 82():35-42. PubMed ID: 7958481
[TBL] [Abstract][Full Text] [Related]
31. Concomitant cytosolic delivery of two immunodominant listerial antigens by Salmonella enterica serovar typhimurium confers superior protection against murine listeriosis.
Igwe EI; Geginat G; Rüssmann H
Infect Immun; 2002 Dec; 70(12):7114-9. PubMed ID: 12438393
[TBL] [Abstract][Full Text] [Related]
32. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
33. Tumor vaccination by Salmonella typhimurium after transformation with a eukaryotic expression vector in mice: impact of a Salmonella typhimurium gene interfering with MHC class I presentation.
Hummel S; Apte RN; Qimron U; Vitacolonna M; Porgador A; Zöller M
J Immunother; 2005; 28(5):467-79. PubMed ID: 16113603
[TBL] [Abstract][Full Text] [Related]
34. Salmonella type III effector SpvC, a phosphothreonine lyase, contributes to reduction in inflammatory response during intestinal phase of infection.
Haneda T; Ishii Y; Shimizu H; Ohshima K; Iida N; Danbara H; Okada N
Cell Microbiol; 2012 Apr; 14(4):485-99. PubMed ID: 22188134
[TBL] [Abstract][Full Text] [Related]
35. Inverted pathogenicity: the use of pathogen-specific molecular mechanisms for prevention or therapy of disease.
Rüssmann H
Int J Med Microbiol; 2004 Apr; 293(7-8):565-9. PubMed ID: 15149032
[TBL] [Abstract][Full Text] [Related]
36. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
Gentschev I; Fensterle J; Schmidt A; Potapenko T; Troppmair J; Goebel W; Rapp UR
BMC Cancer; 2005 Feb; 5():15. PubMed ID: 15703070
[TBL] [Abstract][Full Text] [Related]
37. Immune reaction and survivability of salmonella typhimurium and salmonella infantis after infection of primary avian macrophages.
Braukmann M; Methner U; Berndt A
PLoS One; 2015; 10(3):e0122540. PubMed ID: 25811871
[TBL] [Abstract][Full Text] [Related]
38. Induction of CD8+ T lymphocytes by Salmonella typhimurium is independent of Salmonella pathogenicity island 1-mediated host cell death.
Wijburg OL; Van Rooijen N; Strugnell RA
J Immunol; 2002 Sep; 169(6):3275-83. PubMed ID: 12218147
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
